ITI Using SCT800 Alone or Combining Daratumumab in Hemophilia A Adolescents and Adults With High Titer Inhibitor
The Outcome Comparison of Immune Tolerance Induction Therapy Using SCT800 Combined With Daratumumab or SCT800 Alone in Hemophilia A Adolescents and Adults With High Titer Inhibitor: a Non-randomized Controlled Trial
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Phase 4
Contacts and Locations
Study Contact
Study Contact
- Name: Wei Liu
- Phone Number: +8613820261971
- Email: liuwei1@ihcams.ac.cn
Study Contact Backup
- Name: Lei Zhang
- Email: zhanglei1@ihcams.ac.cn
Study Locations
-
-
-
Tianjin, China
- Recruiting
- Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
-
Contact:
- Shuo Chen
- Email: chenshuo@ihcams.ac.cn
-
Contact:
- L Liu
- Email: gcp@ihcams.ac.cn
-
Principal Investigator:
- Lei Zhang
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria
- Moderate or severe hemophilia A;
- Aged 14-66 years old;
- Inhibitor positive at 2 consecutive visits;
- Inhibitor titer > 10 BU at the screening visit.
Exclusion Criteria:
- The patient has contraindications to drug ingredients or hamster protein allergy;
- Suffering from other immune diseases or Using immunosuppressant IS to treat another disease(s);
- Failed systemic ITI treatment in history;
- Poor patients compliance;
- The investigator believes that there are any other reasons that make the patient unsuitable to participate in this study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: SCT800 combined with Daratumumab
ITI using low-dose domestic rFVIII (SCT800) (50IU/kg TIW) and treated with Daratumumab 8mg/kg 4-8 times.
Other immunosuppressants could be added after 3 months.
|
SCT800 50IU/kg TIW alone or treated with Daratumumab 8mg/kg 4-8 times
Other Names:
|
|
Active Comparator: SCT800 alone
ITI using low-dose domestic rFVIII (SCT800) (50IU/kg TIW) alone.
Other immunosuppressants could be added after 3 months.
|
SCT800 50IU/kg TIW alone
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
success rate of ITI success rate of ITI success rate of ITI success rate of ITI
Time Frame: 12 months
|
Inhibitor titre <0.6 BU⁄mL
|
12 months
|
|
Success rate and partial success rate of ITI after 3-month treatment
Time Frame: 3 months
|
Inhibitor titre <0.6 BU⁄mL
|
3 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
ITI success time
Time Frame: 12 months
|
time to successful tolerance
|
12 months
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Lei Zhang, Chinese Academy of Medical Science and Blood Disease Hospital
- Principal Investigator: Renchi Yang, Chinese Academy of Medical Science and Blood Disease Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- IIT2022035
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.